Last reviewed · How we verify
NOAC
NOAC, marketed by Attikon Hospital, is a novel oral anticoagulant currently available in the market. The drug's key strength lies in its specific mechanism of action, which interacts with a targeted biological pathway to achieve its therapeutic effect. A primary risk is the expiration of the key composition patent in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | NOAC |
|---|---|
| Also known as | Non-vitamin K oral anticoagulant, Edoxaban, Apixaban, Rivaroxaban, Dabigatran |
| Sponsor | Attikon Hospital |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Implementing Prescriber-Pharmacist Collaborative Care for Evidence-based Anticoagulant Use (NA)
- Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure (PHASE4)
- FENOX Trial (Comparative Effectiveness of Fexuprazan Co-therapy in Patients Receiving Non-Vitamin K Antagonist Oral Anticoagulants) (NA)
- SENIOR: Stroke Prevention in the Elderly by Patent Foramen Ovale closuRe vs Anticoagulation
- AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms (PHASE3)
- A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolism (VTE)
- SIMPLAAFY Clinical Trial (NA)
- Rivaroxaban vs Warfarin in Patients With Mechanical Heart Valves (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NOAC CI brief — competitive landscape report
- NOAC updates RSS · CI watch RSS
- Attikon Hospital portfolio CI